FDA advisers to weigh risks and benefits of Novavax s Covid-19 vaccine kesq.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kesq.com Daily Mail and Mail on Sunday newspapers.
After more than a year with two types of COVID-19 vaccines in use in the United States, another will be up for consideration by the U.S. Food and Drug Administration this week.
The FDA is poised to consider authorization for Novavax s COVID vaccine this month. The company is hoping to find a niche among some of the unvaccinated who might agree to a more traditional protein vaccine.
The Novavax vaccine appears to be about 90% effective at preventing mild, moderate and severe COVID-19, Food and Drug Administration scientists say in an analysis of the company's data.
After more than a year with two types of Covid-19 vaccines in use in the United States, another will be up for consideration by the US Food and Drug Administration